Organon & Co. (BMV:OGN)

Market Cap	44.46B
Revenue (ttm)	128.64B
Net Income (ttm)	15.33B
Shares Out	n/a
EPS (ttm)	58.81
PE Ratio	2.90
Forward PE	2.30
Dividend	17.03 (10.01%)
Ex-Dividend Date	May 12, 2025

Volume	11,620
Average Volume	1,146
Open	170.19
Previous Close	171.23
Day's Range	170.19 - 170.19
52-Week Range	163.00 - 426.40
Beta	n/a
RSI	4.54
Earnings Date	May 1, 2025

About Organon & Co.

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 10,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: OGN

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Financial numbers in USD